Digital Repository

Prognostic factors and pattern of long-term recovery with MLC601 (NeuroAiD™) in the chinese medicine neuroAiD efficacy on stroke recovery - extension study

Show simple item record Venketasubramanian, N. Lee, C.F. Young, S.H. Tay, S.S. Umapathi, T. Lao, A.Y. Gan, H.H. Chua, C.L. Wijekoon, N. de Silva, H.A. Hiyadan, J.H. Suwanwela, N.C. Wong, K.S. Poungvarin, N. Eow, G.B. Chen, C.L. CHIMES-E Study Investigators 2017-07-05T07:49:21Z 2017-07-05T07:49:21Z 2017
dc.identifier.citation Cerebrovascular Diseases. 2017; 43(1-2): 36-42 en_US
dc.identifier.issn 1015-9770 (Print)
dc.identifier.issn 1421-9786 (Electronic)
dc.identifier.issn 1015-9770 (Linking)
dc.description Indexed In MEDLINE en_US
dc.description.abstract BACKGROUND: The Chinese Medicine NeuroAiD Efficacy on Stroke recovery - Extension (CHIMES-E) study is among the few acute stroke trials with long-term outcome data. We aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of MLC601 over 2 years. METHODS: The CHIMES-E study evaluated the 2 years outcome of subjects aged ≥18 years with acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) score 6-14, pre-stroke modified Rankin Scale (mRS) score ≤1 included in a multicenter, randomized, double-blind, placebo-controlled trial of MLC601 for 3 months. Standard stroke care and rehabilitation were allowed during follow-up with mRS score being assessed in-person at month (M) 3 and by telephone at M1, M6, M12, M18 and M24. RESULTS: Data from 880 subjects were analyzed. There was no difference in baseline characteristics between treatment groups. The proportion of subjects with mRS score 0-1 increased over time in favor of MLC601 most notably from M3 to M6, thereafter remaining stable up to M24, while the proportion deteriorating to mRS score ≥2 remained low at all time points. Older age (p < 0.01), female sex (p = 0.06), higher baseline NIHSS score (p < 0.01) and longer onset to treatment time (OTT; p < 0.01) were found to be predictors of poorer outcome at M3. Greater treatment effect, with more subjects improving on MLC601 than placebo, was seen among subjects with 2 or more prognostic factors (OR 1.65 at M3, 1.78 at M6, 1.90 at M12, 1.65 at M18, 1.39 at M24), especially in subjects with more severe stroke or longer OTT. CONCLUSIONS: The sustained benefits of MLC601 over 2 years were due to more subjects improving to functional independence at M6 and beyond compared to placebo. Selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT delay, as well as a long follow-up period, may improve the power of future trials investigating the treatment effect of neuroprotective or neurorestorative therapies. en_US
dc.language.iso en_US en_US
dc.publisher Karger en_US
dc.subject Stroke Recovery en_US
dc.title Prognostic factors and pattern of long-term recovery with MLC601 (NeuroAiD™) in the chinese medicine neuroAiD efficacy on stroke recovery - extension study en_US
dc.type Article en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


My Account